Date published: 2026-7-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

ZFP101 CRISPR/Cas9 KO Plasmid (m): sc-423758

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • ZFP101 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ZFP101 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    ZFP101 CRISPR/Cas9 KO Plasmid (m)

    sc-423758
    20 µg
    $397.00

    Overview

    Mouse Zfp101 encodes ZFP101, a predicted C2H2-type zinc finger protein implicated in sequence-specific DNA binding and transcriptional regulation. As a putative nuclear factor, ZFP101 may contribute to chromatin-associated control of gene expression programs that coordinate cell state transitions such as proliferation, differentiation, and stress-responsive transcription. Perturbation of zinc finger–mediated regulatory networks is broadly relevant to mechanisms underlying developmental phenotypes and dysregulated transcription observed in complex diseases, including cancer and neurodevelopmental disorders. Zfp101 therefore serves as a useful locus for interrogating how transcriptional repressors/activators shape downstream signaling and genome-wide expression patterns in mouse model systems.

    ZFP101 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Zfp101 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Zfp101 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Zfp101 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ZFP101 protein expression.

    This CRISPR knockout system enables efficient generation of Zfp101-deficient cell models for investigation of ZFP101 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Zfp101 exon(s) critical for ZFP101 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Zfp101 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by ZFP101 CRISPR/Cas9 KO Plasmid (m) and ZFP101 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Zfp101 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by ZFP101 HDR Plasmid (m) and ZFP101 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Zfp101 homology arms to support homology-directed repair at defined Zfp101 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.